INTRACELLULAR PHARMACOKINETICS OF 2-CHLORODEOXYADENOSINE IN LEUKEMIA-CELLS FROM PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA

被引:0
|
作者
ALESSISEVERINI, S
GATI, WP
BELCH, AR
PATERSON, ARP
机构
[1] UNIV ALBERTA, DEPT PHARMACOL, EDMONTON, AB T6G 2H7, CANADA
[2] CROSS CANC INST, DEPT MED, EDMONTON, AB T6G 1Z2, CANADA
关键词
2-CHLORODEOXYADENOSINE (2-CDA); NITROBENZYLTHIOINOSINE (NBMPR); CHRONIC LYMPHOCYTIC LEUKEMIA (CLL); NUCLEOSIDE TRANSPORT INHIBITION; TRANSPORTER-MEDIATED EFFLUX; EFFLUX BLOCKADE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
2-Chlorodeoxyadenosine (2-CdA) is an important agent in the treatment of hairy cell leukemia and chronic lymphocytic leukemia (CLL). Others have reported that levels of 2-CdA phosphates present in human leukemia cells decline rapidly when the cells are in 2-CdA-free medium (Santana et al. J Clin Oncol 1991; 9: 416-422). In the present study, time-courses of 2-CdA lass from CLL cells were biexponential: the mean half-life of the initial phase was 0.30 +/- 0.18 h; the presence of 0.5 mu M nitrobenzylthioinosine (NBMPR, a classical inhibitor of nucleoside transport) in the suspending medium, significantly decreased the initial rate of 2-CdA efflux (mean half-life, 0.43 +/- 0.22 h). As a consequence, AUCs (areas under time-course plots) were significantly higher in the NBMPR-treated cells (4.56 +/- 2.01 pmol . h/10(6) cells, n = 19) than in untreated control cells (3.83 +/- 1.74 pmol . h/10(6) cells; n = 19). 2-CdA was the principal efflux product released into the medium from 2-CdA-loaded CLL cells. We conclude that nucleoside transport processes contribute to the efflux of 2-CdA from CLL cells and that NBMPR may be useful as a retentive agent.
引用
收藏
页码:1674 / 1679
页数:6
相关论文
共 50 条
  • [21] ORAL 2-CHLORODEOXYADENOSINE (CDA) AS PRIMARY-TREATMENT FOR SYMPTOMATIC CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL)
    JULIUSSON, G
    JOHNSON, SAN
    CHRISTIANSEN, I
    KIMBY, E
    BJORKHOLM, M
    LARFARS, G
    LILIEMARK, J
    BLOOD, 1993, 82 (10) : A141 - A141
  • [22] 2-CHLORODEOXYADENOSINE (CDA) THERAPY IN ADVANCED CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL) AND IN WALDENSTROMS MACROGLOBULINEMIA (WM)
    DELANNOY, A
    FERRANT, A
    MARTIAT, P
    MONTFORT, L
    DOYEN, C
    SOKAL, G
    MICHAUX, JL
    BLOOD, 1993, 82 (10) : A562 - A562
  • [23] SURVIVAL OF PREVIOUSLY TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA FOLLOWING IV-CLADRIBINE (2-CHLORODEOXYADENOSINE, CDA)
    JULIUSSON, G
    LILIEMARK, J
    BLOOD, 1994, 84 (10) : A462 - A462
  • [24] POTENT ACTIVITY OF 2-CHLORODEOXYADENOSINE IN CHRONIC LYMPHOCYTIC-LEUKEMIA, HAIRY-CELL LEUKEMIA, AND AUTOIMMUNE HEMOLYTIC-ANEMIA
    CARSON, DA
    PIRO, LD
    WASSON, DB
    CARRERA, CJ
    BEUTLER, E
    PEDIATRIC RESEARCH, 1988, 24 (01) : 114 - 114
  • [25] Induction of apoptosis by 2-chlorodeoxyadenosine in B cell chronic lymphocytic leukemia
    R Castejón
    JA Vargas
    M Briz
    E Berrocal
    Y Romero
    JC Gea-Banacloche
    MN Fernández
    A Durántez
    Leukemia, 1997, 11 : 1253 - 1257
  • [26] Induction of apoptosis by 2-chlorodeoxyadenosine in B cell chronic lymphocytic leukemia
    Castejon, R
    Vargas, JA
    Briz, M
    Berrocal, E
    Romero, Y
    GeaBanacloche, JC
    Fernandez, MN
    Durantez, A
    LEUKEMIA, 1997, 11 (08) : 1253 - 1257
  • [27] 2-chlorodeoxyadenosine (2-CdA) in chronic lymphocytic leukemia refractory to fludarabine?
    Schirmer, M
    Michlmayr, G
    Geisen, F
    Konwalinka, G
    LEUKEMIA, 1996, 10 (07) : 1253 - 1254
  • [28] PREDNISOLONE LEVELS IN PLASMA AND LEUKEMIA-CELLS DURING THERAPY OF CHRONIC LYMPHOCYTIC-LEUKEMIA
    PANESAR, NS
    BIRD, CC
    ROBERTS, BE
    CHILD, JA
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1984, 73 (01) : 66 - 68
  • [29] ACUTE ONSET OF SEVERE AUTOIMMUNE HEMOLYTIC-ANEMIA AFTER TREATMENT WITH 2-CHLORODEOXYADENOSINE FOR CHRONIC LYMPHOCYTIC-LEUKEMIA
    FLEISCHMAN, RA
    CROY, D
    AMERICAN JOURNAL OF HEMATOLOGY, 1995, 48 (04) : 293 - 293
  • [30] 2-CHLORODEOXYADENOSINE FOR PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA RESISTANT TO FLUDARABINE (VOL 328, PG 812, 1993)
    SAVEN, A
    NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (24): : 1796 - 1796